NCT03695250

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

TERMINATEDPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2018-10-16Est. Completion: 2020-11-24

Enrollment target: 8 participants

Locations

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Other microbiome trials you might be interested in

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsPhase 1Recruiting

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric CancerExtragonadal Yolk Sac TumorsGlypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), phar…

Goodyear, United StatesEst. completion May 30, 2028

View Trial →

Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After SurgeryPhase 4Recruiting

Hepato Cellular Carcinoma

This study evaluates ebastine, an FAK (focal adhesion kinase) inhibitor, as adjuvant therapy to reduce the risk of recur…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.